StockNews.com Upgrades Lexicon Pharmaceuticals (NASDAQ:LXRX) to Sell

StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) to a sell rating in a research note published on Monday morning.

Separately, Needham & Company LLC reiterated a hold rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, April 11th.

Lexicon Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ:LXRX opened at $1.63 on Monday. The stock has a market cap of $401.37 million, a PE ratio of -2.04 and a beta of 1.27. The company has a quick ratio of 5.58, a current ratio of 5.60 and a debt-to-equity ratio of 1.07. Lexicon Pharmaceuticals has a 12-month low of $0.92 and a 12-month high of $3.79. The business has a 50 day moving average of $2.38 and a 200-day moving average of $1.70.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. The company had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.68 million. As a group, equities research analysts forecast that Lexicon Pharmaceuticals will post -0.71 earnings per share for the current year.

Institutional Trading of Lexicon Pharmaceuticals

Large investors have recently bought and sold shares of the business. BVF Inc. IL boosted its stake in shares of Lexicon Pharmaceuticals by 22.2% during the fourth quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company’s stock valued at $37,387,000 after purchasing an additional 4,440,300 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Lexicon Pharmaceuticals by 34.0% in the third quarter. Vanguard Group Inc. now owns 5,256,288 shares of the biopharmaceutical company’s stock valued at $12,614,000 after buying an additional 1,334,318 shares during the period. BlackRock Inc. raised its holdings in Lexicon Pharmaceuticals by 27.4% during the 3rd quarter. BlackRock Inc. now owns 5,760,000 shares of the biopharmaceutical company’s stock worth $13,823,000 after purchasing an additional 1,240,171 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Lexicon Pharmaceuticals in the 4th quarter worth approximately $1,194,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at $1,155,000. 74.70% of the stock is owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.